Inaug.-diss.--Basel. / Lebenslauf.

Thesis (M.S.)--University of Wisconsin--Madison, 1969. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (Ph.D.)--University of North Carolina at Greensboro, 2007. / Title from PDF t.p. (viewed Oct. 22, 2007). Directed by Nancy Myers; submitted to the Dept. of English. Includes bibliographical references (p. 209-228).

The SA Code of Practice for the Marketing of Medicines was formulated in an attempt to reduce the cost of medicines, thus ruling out certain marketing practices. This research report investigated what the perceived impact of the Code may be on customer equity in an already volatile industry. Quantitative, cross-sectional research was undertaken. A pre-tested, selfadministered, e-mail survey based on the regulations of the Code was distributed to key account retail pharmacies of a particular pharmaceutical company in South Africa. Four hypotheses were statistically tested at significance levels of 0,1 %, 1 % and 5 %. Inferences were then drawn based on the quantitative analyses. The results show that the market is in favour of the “Code-not-condoned” value, brand and relationship equity marketing practices; thus the Code’s impact may be perceived as negative. Pharmaceutical firms should be careful in selecting “Code-condoned” marketing practices, as these may not contribute to customer equity. This aspect adds to the complexity of choosing the correct marketing practices. It is recommended that only those marketing practices not contributing to customer equity should be outlawed by the Code. The indication is that the Code’s impact may reach further than just attempting to drive down the price of medicines; it may also impact the long term value of a pharmaceutical firm. Copyright / Dissertation (MBA)--University of Pretoria, 2010. / Gordon Institute of Business Science (GIBS) / unrestricted

Thesis (M.S.)--Ohio University, November, 1995. / Title from PDF t.p.

Thesis (Ph. D.)--Cornell University, 1991. / Vita. Includes bibliographical references (leaves 262-269).

No description available.

Thesis. 1979. Ph.D.--Massachusetts Institute of Technology. Dept. of Economics. / MICROFICHE COPY AVAILABLE IN ARCHIVES AND DEWEY. / Bibliography: leaves 176-179. / This thesis examines the effect that federal regulation of the product quality of new drugs (through safety and efficacy requirements) has had on the flow of new drugs onto the market place. The approach is to econometrically estimate these effects using disaggregated therapeutic class data from the 1970's. There are two primary estimations. First, the current effects of regulation on the production function relation between introductions and research expenditures are estimated. Second, the indirect effects of regulation on research effort are estimated in a research expenditures equation. These estimates are then combined to estimate the overall effect of regulation on introductions in the current era. In addition to the basic estimations described above, several important subsidiary issues are treated in the thesis. One is a discussion of the decline in new drug introductions of the 1962 era in terms of its individual therapeutic class components. This discussion gives strong support to the position that nonregulatory factors precipitated that decline in the rate of product introductions. Also, the project selection process of major pharmaceutical companies is examined in great detail. That discussion, and some econometric tests of hypotheses generated, clearly demonstrates that in order to predict how firms will respond to changes in environmental factors affecting profitability, one must first understand how firms collect, evaluate, and apply information concerning those factors. / Ph.D.

Abstract Pharmaceutical industry can be regard as one of the knowledge-intensive industries. Designing a sales promotion for the new medicine really has very great influence on new products to enter the market successfully not only because of its time-consuming and enormously expensive research and development process, but also owing to the government¡¦s control on the production and sales of pharmaceuticals. However, the pharmaceutical products in the domestic market are all generics which are usually lacking of innovation. Therefore, few companies promote their new products through the ¡§New Product Preannouncement¡¨ to raise success rate for the new products. Through the specific case study, my study analyzes and reviews the pluses and minuses of the new product preannouncement activity that Standard Pharmaceutical Company has done with its medicine-grade Cordyceps Sinensis. Moreover, my study also analyzes and reviews whether the preannouncement activity is implemented with thoughtful consideration. In this way, other companies which intend to implement the new product preannouncement activity may take it for reference. The following are the most important conclusions of my study: 1. In the medicine market, new product preannouncement strategy is recommended to raise the success rate for the new products sales. 2. The quality of the new product preannouncement design influences the success rate for the new products sales. 3. While engaging in new product preannouncement, it¡¦s better to depict the functions and attributes of the new products in detail. 4. The first issuer of new generics may implement the new product preannouncement after obtaining the medicine license from National Health Administration. However, the preannouncement activity can be planned in advance. 5. To promote new product preannouncement, 4W2H should be considered at the same time.( 4W means ¡§Who¡¨, ¡§When¡¨, ¡§What¡¨ and ¡§Why¡¨, while 2H represents ¡§How much¡¨ and ¡§How to do¡¨) Keyword¡Gnew product preannouncement, Pharmaceutical industry

Dissertation (Ph.D.)--Auburn University, 2009. / Abstract. Includes bibliographic references.